ErbB-2/HER-2 protein expression, serum tumour necrosis factor-α (TFM-α) and soluble tumour necrosis factor receptor-2 (TNFR-2) concentrations in human carcinoma of the uterine cervix

Z. Melczer, F. Bánhidy, S. Csömör, P. Siklós, O. Dworak, K. Cseh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The expression of erbB-2 protein (by immunohistochemistry), serum TNF-α, soluble TNF-receptor 2 (sTNFR-2, ELISA) concentrations and mitogenic (LPS, ConA, PHA) induced TNF-α production of the peripheral blood mononuclear cells (PBMNC) were studied in 91 (UICC Stage 1: 39, Stage 2: 33, Stage 3: 14, Stage 4: 5) patients with carcinoma of the uterine cervix. During a follow-up period of seven years 30 patients died (Stage 4: 5, Stage 3: 12, Stage 2: 11, Stage 1: 2). ErbB-2 protein expression was significantly more frequent in patients with UICC Stages 3-4 (14/19), and in those with fatal outcomes (14/30, p <0.0001, chi-square test). Serum TNF-α (2.70 ± 0.69 pg/ml) and sTNFR-2 (3.85 ± 1.05 ng/ml) concentrations were significantly lower in cancer patients (p <0.0001, Mann-Whitney test) as compared to 64 age-matched control women (TNF-α: 4.32 ± 0.36, TNFR-2: 4.85 ± 0.82). The mitogenic induced TNF-α production of PBMNC was also significantly less with all the three mitogens applied (LPS: 35.24 ± 8.84, ConA: 26.28 ± 7.81, PHA: 20.48 ± 7.04 pg/1 million of cells/24 hours, p <0.0001) as compared to the controls (LPS: 65.33 ± 8.82, ConA: 51.00 ± 8.87, PHA: 41.80 ± 9.01). Serum TNF-α, sTNFR-2 concentrations and the mitogenic induced TNF-α production of PBMNC was significantly decreased in patients with erbB-2 positivity as compared to those with negativity. In conclusion the expression of the oncoprotein and the lower levels of the members of the TNF system seem to be poor prognostic parameters in patients with carcinoma of the uterine cervix.

Original languageEnglish
Pages (from-to)138-142
Number of pages5
JournalEuropean Journal of Gynaecological Oncology
Volume24
Issue number2
Publication statusPublished - 2003

Fingerprint

Receptors, Tumor Necrosis Factor, Type II
Cervix Uteri
Blood Proteins
Tumor Necrosis Factor-alpha
Carcinoma
Blood Cells
Fatal Outcome
Tumor Necrosis Factor Receptors
Oncogene Proteins
Chi-Square Distribution
Serum
Mitogens
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry

Keywords

  • Cervical cancer
  • ErbB-2
  • TNF-α
  • TNFR-2

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

@article{728b5f7df23a4444837ee42e6651582c,
title = "ErbB-2/HER-2 protein expression, serum tumour necrosis factor-α (TFM-α) and soluble tumour necrosis factor receptor-2 (TNFR-2) concentrations in human carcinoma of the uterine cervix",
abstract = "The expression of erbB-2 protein (by immunohistochemistry), serum TNF-α, soluble TNF-receptor 2 (sTNFR-2, ELISA) concentrations and mitogenic (LPS, ConA, PHA) induced TNF-α production of the peripheral blood mononuclear cells (PBMNC) were studied in 91 (UICC Stage 1: 39, Stage 2: 33, Stage 3: 14, Stage 4: 5) patients with carcinoma of the uterine cervix. During a follow-up period of seven years 30 patients died (Stage 4: 5, Stage 3: 12, Stage 2: 11, Stage 1: 2). ErbB-2 protein expression was significantly more frequent in patients with UICC Stages 3-4 (14/19), and in those with fatal outcomes (14/30, p <0.0001, chi-square test). Serum TNF-α (2.70 ± 0.69 pg/ml) and sTNFR-2 (3.85 ± 1.05 ng/ml) concentrations were significantly lower in cancer patients (p <0.0001, Mann-Whitney test) as compared to 64 age-matched control women (TNF-α: 4.32 ± 0.36, TNFR-2: 4.85 ± 0.82). The mitogenic induced TNF-α production of PBMNC was also significantly less with all the three mitogens applied (LPS: 35.24 ± 8.84, ConA: 26.28 ± 7.81, PHA: 20.48 ± 7.04 pg/1 million of cells/24 hours, p <0.0001) as compared to the controls (LPS: 65.33 ± 8.82, ConA: 51.00 ± 8.87, PHA: 41.80 ± 9.01). Serum TNF-α, sTNFR-2 concentrations and the mitogenic induced TNF-α production of PBMNC was significantly decreased in patients with erbB-2 positivity as compared to those with negativity. In conclusion the expression of the oncoprotein and the lower levels of the members of the TNF system seem to be poor prognostic parameters in patients with carcinoma of the uterine cervix.",
keywords = "Cervical cancer, ErbB-2, TNF-α, TNFR-2",
author = "Z. Melczer and F. B{\'a}nhidy and S. Cs{\"o}m{\"o}r and P. Sikl{\'o}s and O. Dworak and K. Cseh",
year = "2003",
language = "English",
volume = "24",
pages = "138--142",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "2",

}

TY - JOUR

T1 - ErbB-2/HER-2 protein expression, serum tumour necrosis factor-α (TFM-α) and soluble tumour necrosis factor receptor-2 (TNFR-2) concentrations in human carcinoma of the uterine cervix

AU - Melczer, Z.

AU - Bánhidy, F.

AU - Csömör, S.

AU - Siklós, P.

AU - Dworak, O.

AU - Cseh, K.

PY - 2003

Y1 - 2003

N2 - The expression of erbB-2 protein (by immunohistochemistry), serum TNF-α, soluble TNF-receptor 2 (sTNFR-2, ELISA) concentrations and mitogenic (LPS, ConA, PHA) induced TNF-α production of the peripheral blood mononuclear cells (PBMNC) were studied in 91 (UICC Stage 1: 39, Stage 2: 33, Stage 3: 14, Stage 4: 5) patients with carcinoma of the uterine cervix. During a follow-up period of seven years 30 patients died (Stage 4: 5, Stage 3: 12, Stage 2: 11, Stage 1: 2). ErbB-2 protein expression was significantly more frequent in patients with UICC Stages 3-4 (14/19), and in those with fatal outcomes (14/30, p <0.0001, chi-square test). Serum TNF-α (2.70 ± 0.69 pg/ml) and sTNFR-2 (3.85 ± 1.05 ng/ml) concentrations were significantly lower in cancer patients (p <0.0001, Mann-Whitney test) as compared to 64 age-matched control women (TNF-α: 4.32 ± 0.36, TNFR-2: 4.85 ± 0.82). The mitogenic induced TNF-α production of PBMNC was also significantly less with all the three mitogens applied (LPS: 35.24 ± 8.84, ConA: 26.28 ± 7.81, PHA: 20.48 ± 7.04 pg/1 million of cells/24 hours, p <0.0001) as compared to the controls (LPS: 65.33 ± 8.82, ConA: 51.00 ± 8.87, PHA: 41.80 ± 9.01). Serum TNF-α, sTNFR-2 concentrations and the mitogenic induced TNF-α production of PBMNC was significantly decreased in patients with erbB-2 positivity as compared to those with negativity. In conclusion the expression of the oncoprotein and the lower levels of the members of the TNF system seem to be poor prognostic parameters in patients with carcinoma of the uterine cervix.

AB - The expression of erbB-2 protein (by immunohistochemistry), serum TNF-α, soluble TNF-receptor 2 (sTNFR-2, ELISA) concentrations and mitogenic (LPS, ConA, PHA) induced TNF-α production of the peripheral blood mononuclear cells (PBMNC) were studied in 91 (UICC Stage 1: 39, Stage 2: 33, Stage 3: 14, Stage 4: 5) patients with carcinoma of the uterine cervix. During a follow-up period of seven years 30 patients died (Stage 4: 5, Stage 3: 12, Stage 2: 11, Stage 1: 2). ErbB-2 protein expression was significantly more frequent in patients with UICC Stages 3-4 (14/19), and in those with fatal outcomes (14/30, p <0.0001, chi-square test). Serum TNF-α (2.70 ± 0.69 pg/ml) and sTNFR-2 (3.85 ± 1.05 ng/ml) concentrations were significantly lower in cancer patients (p <0.0001, Mann-Whitney test) as compared to 64 age-matched control women (TNF-α: 4.32 ± 0.36, TNFR-2: 4.85 ± 0.82). The mitogenic induced TNF-α production of PBMNC was also significantly less with all the three mitogens applied (LPS: 35.24 ± 8.84, ConA: 26.28 ± 7.81, PHA: 20.48 ± 7.04 pg/1 million of cells/24 hours, p <0.0001) as compared to the controls (LPS: 65.33 ± 8.82, ConA: 51.00 ± 8.87, PHA: 41.80 ± 9.01). Serum TNF-α, sTNFR-2 concentrations and the mitogenic induced TNF-α production of PBMNC was significantly decreased in patients with erbB-2 positivity as compared to those with negativity. In conclusion the expression of the oncoprotein and the lower levels of the members of the TNF system seem to be poor prognostic parameters in patients with carcinoma of the uterine cervix.

KW - Cervical cancer

KW - ErbB-2

KW - TNF-α

KW - TNFR-2

UR - http://www.scopus.com/inward/record.url?scp=0037248711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037248711&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 138

EP - 142

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 2

ER -